https://scholars.lib.ntu.edu.tw/handle/123456789/594876
標題: | Evolution of systemic treatment for advanced hepatocellular carcinoma | 作者: | Wu T.-C. YING-CHUN SHEN ANN-LII CHENG |
公開日期: | 2021 | 出版社: | John Wiley and Sons Inc | 卷: | 37 | 期: | 8 | 起(迄)頁: | 643-653 | 來源出版物: | Kaohsiung Journal of Medical Sciences | 摘要: | Advanced hepatocellular carcinoma (HCC) was considered an inherently refractory tumor in the chemotherapy era (1950–2000). However, systemic therapy has evolved to molecular targeted therapy and immunotherapy, and nine treatment regimens have been approved worldwide during the past 20 years. The approved regimens target tumor angiogenesis or tumor immunity, the two cancer hallmarks. Recently, the combination of atezolizumab (antiprogrammed cell death ligand 1) and bevacizumab (anti-vascular endothelial growth factor) has improved the efficacy of systemic therapy in treating advanced HCC without excessive toxicities or deterioration of quality of life. This review summarizes the major advances in systemic therapy and provides future perspectives on the next-generation systemic therapy for advanced HCC. ? 2021 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia on behalf of Kaohsiung Medical University. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85109342678&doi=10.1002%2fkjm2.12401&partnerID=40&md5=82a446124f04de1e7bc814f629861131 https://scholars.lib.ntu.edu.tw/handle/123456789/594876 |
ISSN: | 1607-551X | DOI: | 10.1002/kjm2.12401 | SDG/關鍵字: | angiogenesis inhibitor; antineoplastic agent; antineoplastic monoclonal antibody; cytotoxic agent; cytotoxic T lymphocyte antigen 4 antibody; gilvetmab; immune checkpoint inhibitor; unclassified drug; vasculotropin receptor inhibitor; angiogenesis inhibitor; antineoplastic agent; advanced cancer; antiangiogenic therapy; cancer chemotherapy; cancer combination chemotherapy; cancer immunotherapy; history of medicine; human; liver cell carcinoma; molecularly targeted therapy; monoclonal antibody therapy; Review; systemic therapy; immunotherapy; liver cell carcinoma; liver tumor; procedures; vascularization; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。